Skip to main content

Table 3 Comparison of PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Each Molecular Group

From: Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas

  Conventional (n = 429) EBV-positive (n = 32) MSI-high (n = 53)
PD-L1 in tumor cells   *aP < 0.001 *bP < 0.001
 Positive 59 (14%) 15 (47%) 27 (51%)
 Negative 370 (86%) 17 (53%) 26 (49%)
PD-L1 in immune cells   *aP < 0.001  
 Positive 186 (43%) 30 (94%) 28 (53%)
 Absent 243 (57%) 2 (6%) 25 (47%)
CD8+   *aP < 0.001 *bP < 0.001
 High 189 (44%) 30 (94%) 38 (72%)
 Low 240 (56%) 2 (6%) 15 (28%)
FOXP3+   *aP = 0.036  
 High 199 (46%) 21 (66%) 20 (38%)
 Low 230 (54%) 11 (34%) 33 (62%)
PD-1+   *aP < 0.001  
 High 142 (33%) 23 (72%) 16 (30%)
 Low 287 (67%) 9 (28%) 37 (70%)
  1. EBV Epstein-Barr virus, MSI Microsatellite instability; Conventional, EBV-negative and non-MSI-high
  2. P values with statistically significant differences (< 0.05) are marked with an asterisk (*)
  3. aP value between EBV-positive gastric carcinomas and conventional gastric carcinomas
  4. bP value between MSI-high gastric carcinomas and conventional gastric carcinomas